EP3295952A1 — Pharmaceutical formulation comprising glp-1 analogue and preparation method thereof
Assigned to HANGZHOU JIUYUAN GENE ENGINEERING Co Ltd · Expires 2018-03-21 · 8y expired
What this patent protects
The present invention discloses a pharmaceutical composition containing GLP-1 analogs, including GLP-1 analogs, buffers, stabilizers, isotonic agents and preservatives. The present invention has the advantage of providing a formulation suitable for clinical multiple injections by…
USPTO Abstract
The present invention discloses a pharmaceutical composition containing GLP-1 analogs, including GLP-1 analogs, buffers, stabilizers, isotonic agents and preservatives. The present invention has the advantage of providing a formulation suitable for clinical multiple injections by adding some ingredients which can be accepted by the human body and enhancing the stabilization of the physicochemical and biological activity of the GLP-1 analog. This preparation can effectively prevent the active ingredient GLP-1 analogs from degradation, oxidation, precipitation and other factors leading to lose efficacy or crystallization, so as to facilitate transport, long-term preservation and clinical use.
Drugs covered by this patent
- Ozempic (semaglutide) · Novo Nordisk
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.